Logo Image
News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademyShortsSponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
Clinical Operations & Strategy|
Patient Participation
Advertisement

Vernette J. Molloy

Advertisement

Vernette J. Molloy, MBA, RN, is vice president of GCPA, Inc., Fairfax Station, Virginia.

Articles by Vernette J. Molloy

i4-687154-1408625365631.jpg

A Closer Look at 1572: Interpreting the FDA's Statement of Investigator Form

ByMark P. Mathieu,Vernette J. Molloy,Douglas R. Mackintosh
September 1st 2010

Applied Clinical Trials Supplements

A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.

A Closer Look at the 1572: Interpreting the FDA's Statement of Investigator Form

ByMark P. Mathieu,Vernette J. Molloy,Douglas R. Mackintosh
October 1st 2004

Applied Clinical Trials

A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.

Advertisement

Latest Updated Articles

  • i4-687154-1408625365631.jpg
    A Closer Look at 1572: Interpreting the FDA's Statement of Investigator Form

    September 1st 2010

  • A Closer Look at the 1572: Interpreting the FDA's Statement of Investigator Form
    A Closer Look at the 1572: Interpreting the FDA's Statement of Investigator Form

    October 1st 2004



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle

2

ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery

3

HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research

4

ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology

5

ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us